Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00492284 · ClinicalTrials.gov registry record · Phase 2
Reduced Fluence Visudyne-Anti-VEGF-Dexamethasone In Combination for AMD Lesions (RADICAL)
A Phase 2 study, sponsored by QLT.
- Completed
- Registry status
- Phase 2
- Development phase
- 162
- Enrollment target
NCT00492284 is a Phase 2 study that has completed, run by QLT. The registered enrollment target is 162 participants.
The verdict
NCT00492284, a Phase 2 study, has completed, sponsored by QLT.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 162 participants
- Enrollment target
Study Summary
The objective of this study is to determine if combination therapy (reduced-fluence Visudyne followed by Lucentis \[within 2 hours\] or either of two regimens of reduced-fluence Visudyne followed by Lucentis-Dexamethasone triple therapy \[within 2 hours\]) reduces retreatment rates compared with Lucentis monotherapy while maintaining similar vision outcomes and an acceptable safety profile.
Interventions
- DRUG dexamethasone
- DRUG ranibizumab
- DRUG verteporfin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 162 participants |
| Start Date | 2007-07 |
| Est. Completion | 2010-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00492284
The ClinicalTrials.gov registry entry for NCT00492284 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 162 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is QLT, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which dexamethasone is the first listed.
NCT00492284 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00492284 about?
NCT00492284 is a clinical study titled "Reduced Fluence Visudyne-Anti-VEGF-Dexamethasone In Combination for AMD Lesions (RADICAL)". The objective of this study is to determine if combination therapy (reduced-fluence Visudyne followed by Lucentis \[within 2 hours\] or either of two regimens of reduced-fluence Visudyne followed by Lucentis-Dexamethasone triple therapy \[within 2 hours\]) reduces retreatment rates compared with Luc...
What is the current status of trial NCT00492284?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 162 participants. The study started on 2007-07. Estimated completion is 2010-05.
What interventions are being tested in trial NCT00492284?
The interventions under investigation include: dexamethasone (DRUG), ranibizumab (DRUG), verteporfin (DRUG).
Who is sponsoring clinical trial NCT00492284?
This trial is sponsored by QLT, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.